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Summary We have investigated the effects of 50min whole-body hyperthermia (WBH; 15 min equilibration
followed by 41°C for 35min) on the toxicity and pharmacokinetics of the radiosensitizer Ro 03-8799 in mice.
WBH markedly reduced Ro 03-8799 LDSO,7d from 779 to 259 igg-1 (P<0.001). Pharmacokinetics were
studied at 175 pgg 1 (-0.6WBHLDSO57d) with and without heat and 437,igg-1 (-0.6 control LDSO/7d)
without heat. WBH increased Ro 03-8799 plasma concentrations and prolonged its elimination t112 by 26%
(P<0.01). Total plasma area under the curve (AUC,,_- ) was increased by 22%. but was still <50% of the
unheated high-dose value. Ro 03-8799 concentrated 300-400% in tumour and brain relative to plasma.
Absolute tumour and brain levels were unaltered by WBH, giving reduced tissue/plasma ratios. WBH greatly
inhibited glomerular filtration (51Cr EDTA clearance) during heating, contributing to the increased plasma
Ro 03-8799 concentrations. WBH increased peak plasma concentrations of the Ro 03-8799 N-oxide
metabolite Ro 31-0313 by 61%, and the fl-phase AUC of i.v. administered Ro 31-0313 by 36%. Since Ro 31-
0313 levels were increased to a greater extent after Ro 03-8799 and WBH than Ro 31-0313 and WBH, WBH
must both increase metabolite production and decrease its plasma clearance. WBH had no effect on Ro 31-
0313 tumour concentrations or its exclusion from brain. These complex effects of WBH on Ro 03-8799
pharmacokinetics may contribute to the enhanced toxicity, possibly through hyperthermia-stimulated
bioreductive drug activation, but do not wholly explain it.
The curability of many tumours by radiotherapy may be
limited by the presence of radioresistant hypoxic tumour
cells. Electron affinic compounds such as the nitroimidazoles
act as hypoxic cell radiosensitizers and are also preferen-
tially cytotoxic towards these cells (Adams et al., 1976).
Hyperthermia enhances the tumour cytotoxicity of the
2-nitroimidazole radiosensitizer misonidazole (MISO;
1-(2-nitroimidazol-1-yl)-3-methoxy-2-propanol) both in vitro
(Stratford and Adams, 1977) and in vivo (Bleehen et al.,
1977; George et al., 1977) but also increases its acute
lethality in mice (Overgaard, 1979).
MISO is likely to produce sub-optimal radiosensitization
in man because dose-limiting neurotoxicity limits achievable
tumour concentrations (see Workman, 1983). Recent studies
have shown that 2-nitroimidazoles substituted with basic side
chains are more potent radiosensitizers than MISO in vitro
(Smithen et al., 1980), with shorter half-lives and hence lower
tissue exposures in vivo (Williams et al., 1982). One of these,
Ro 03-8799 [oc-[(2-nitro-1-imidazolyl)methyl]-1-piperidine-
ethanol], is now under clinical evaluation (Roberts et al.,
1986; Saunders et al., 1984). The basicity and redox
properties of this molecule result in improved radio-
sensitizing potency both in vitro (Dennis et al., 1985; Watts
and Jones, 1985; Smithen et al., 1980) and in vivo (Williams
et al., 1982), together with the achievement of appreciably
higher in vivo tumour/plasma ratios compared to MISO
(Allen et al., 1984; Roberts et al., 1986). This has led to
the expectation that Ro 03-8799 may offer a significant
therapeutic advantage. Since, on the basis of intracellular
concentrations (Dennis et al., 1985), Ro 03-8799 is about 4
times more toxic than MISO towards hypoxic cells (M.E.
Watts & M. Woodcock, Personal communication), there is
potential for its use in conjunction with hyperthermia.
Despite considerable interest in the combination of
radiosensitizers and other drugs with hyperthermia, there
have been very few studies of the effects of heat on
nitroimidazole drug pharmacokinetics. We have examined
the effects of whole-body hyperthermia (WBH) on the
toxicity and pharmacokinetics of Ro 03-8799 in mouse
plasma, brain and tumour to address the following
questions: (1) Does WBH alter the acute toxicity of Ro 03-
8799? (2) Does WBH affect the pharmacokinetics and
potential pharmacodynamics of Ro 03-8799? (3) Do the
interactions have a pharmacokinetic explanation and/or
offer new information on the effects of WBH on drug
metabolism?
Materials and methods
Mice and tumours
Adult C3H/He mice were obtained from our own breeding
colony and from Olac Ltd (Bicester, UK). Males were used
in most experiments but females were used occasionally.
Mice were allowed food (PRD nuts; Labsure, Poole, Dorset,
UK) and water ad lib, and were used at 25-35 g body weight.
The KHT sarcoma was grown in the gastrocnemius muscle
of the hind leg as previously described (Twentyman et al.,
1979). Mice were treated bearing tumours in the size range
0.4-0.8g.
Drugs and radionuclides
Ro 03-8799, its N-oxide Ro 31-0313 [a-[(2-nitro-1-
imidazolyl)methyl]-1-piperidine-ethanol 1-oxide] and the
internal standard Ro 07-1902 [1-(2-nitroimidazol-1-yl)
allyloxy propanol] were supplied in powder form by Roche
(Welwyn Garden City, UK). Ro 03-8799 was provided as the
hydrochloride salt and all doses and concentrations are
reported as the free base. Chromium 5ICr EDTA solution
(Amersham International, Amersham, UK) was supplied at
100pCiml- 1 with a specific activity of 1-2mCi mg -
chromium.
Nitroimidazoles were administered in Hanks' buffered salt
solution (HBSS, pH 7.4) at a fixed volume of 0.01 ml g- 1
body wt i.v. via the tail vein. Ro 03-8799 was injected over
35-40 sec to avoid vascular shock (Williams et al., 1982).
Ro 31-0313 was administered as an i.v. bolus. 51Cr EDTA
was diluted in HBSS to a concentration of 40 jiCiml-1 and
injected i.v. as a bolus at either 0.005 or 0.01 mlg 1 body wt
via the tail vein. All substances were given 10min before
WBH, to allow peak tumour concentrations to be obtained.
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Hyperthermia
The method of inducing WBH in mice was similar to that
previously described by Honess and Bleehen (1982). Briefly,
unanaesthetised unrestrained mice were enclosed in a wire
mesh cage and placed under a fan in an incubator (type C2,
Laboratory and Electrical Engineering Co., Nottingham,
UK; approximate volume 3.5m3) set at 44°C. Fresh air was
pumped continually into the incubator. Three to six mice
were treated per 50min session.
Temperatures were measured using a BAT-12 digital
thermometer (±_0.1 C) fitted with RET-3 murine rectal
probes (Bailey's Instruments, Saddle Brooke, NJ, USA) or
fine copper/constantan thermocouples as appropriate.
Sample preparation
Whole blood was removed under diethyl-ether anaesthesia
by cardiac puncture into heparinised syringes. Plasma was
obtained by centrifugation in a refrigerated Sorvall RC-5B
Superspeed centrifuge (Du Point Instruments, USA) at
4000g for 15min. Nitroimidazoles were extracted from
plasma by the addition of 10 vol acetonitrile (Walkerburn,
Scotland, UK) containing internal standard (Ro 07-1902 at
2.5mg - 1) and centrifuged at 2000g for 15min. Aliquots of
supernantant were evaporated to dryness in vacuo using a
Savant Speed Vac Concentrator coupled to a Model 100A
Refrigerated Condensation trap (Savant, Farmingdale, NY,
USA). Residues were resuspended in running buffer prior to
high-performance liquid chromatography (HPLC) analysis.
After exsanguination animals were killed by cervical
dislocation and tumour and brain samples rapidly excised
and snap-frozen in dry ice at -70°C to prevent ex vivo
metabolism. Individual tissue samples were homogenised
(33% w/v in distilled water) in all-glass homogenisers before
extraction and HPLC analysis as described for plasma.
Samples were handled at 4°C and stored at -20°C for up to
4 weeks before analysis.
High-performance liquid chromatography
Concentrations of Ro 03-8799 and Ro 31-0313 in plasma
and tissue homogenates were determined using the paired-
ion, reverse-phase HPLC method of Malcolm et al. (1983),
with minor modifications. Briefly, analyses were carried out
using Waters modular HPLC equipment (Waters Assoc.,
Milford, Mass., USA) which included a Model 6000A
chromatography pump, a Waters Intelligent Sample
Processor (WISP), a model 440 fixed-wavelength UV
detector and a Z-module. Separations were performed on
Waters reverse-phase octadecylsilane (C18) Rad-Pak
jiBondapak columns (10cm x 8mm i.d., 10,um beads) and
eluted isocratically with 17% acetonitrile in 0.2 M
glycine/hydrochloric acid buffer containing 5mM heptane
sulphonic acid (Fisons, Loughborough, UK), pH2.45, at a
flow rate of 4.5mlmin-1. The absorbance of the effluent
was monitored at 313 nm. Ro 03-8799 and Ro 31-0313 were
identified by co-chromatography with authentic material and
quantitated by peak-height ratio with reference to standard
curves which were linear over the range 0.05-500pgml-1.
Same-day coefficients of variation for plasma spiked at
20pgml-l were 6.8% for Ro 03-8799 and 5.9% for Ro 31-
0313 (n=8). The lower limit of detection was 0.05 gml-l
giving an on-column detection of 1-2ng for a 20pl injection
volume. Recoveries were always >95%. Run times were
<6min.
5l Cr EDTA clearance
The effect of WBH on glomerular filtration rate (GFR) was
assayed by measuring 51Cr EDTA clearance (Chantler et al.,
1969). Aliquots of plasma from 51Cr EDTA treated mice
were counted for 5min in a 1185 Series Automatic Gamma
Counting System, Model 8931 (Searle Analytic Inc., Illinois,
USA). Diluted injection solution was counted at the same
time.
Pharmacokinetic parameters
Pharmacokinetic parameters were calculated as described in
detail elsewhere (White & Workman, 1980; Workman &
Brown, 1981) using a one- or two-compartment model with
curve stripping as appropriate. Apparent volumes of
distribution (Vd,e, and Vdarea) were calculated using
established methods (Wagner, 1975). Lines of best fit, with
standard errors, were calculated by least-squares linear
regression analysis yielding half-lives with 95% confidence
limits. Plasma area under the concentration x time curve
(AUC) was calculated from the expression AUCO- =Colk,
where CO is the concentration at time 0 and k is the
elimination rate constant, or from the equation AUCO_0
=A/ax+B/I, as appropriate. Tissue AUCO-, from time 0 to
time t was estimated by Simpson's rule. The remaining
AUC,-,, was derived from Cl/k for the tissue concerned.
Determination ofacute LD50/7d
The effect of WBH on the acute LDSO,7d of Ro 03-8799 was
determined using both tumour and non-tumour bearing
mice, there being no apparent difference in response. Graded
doses were given, ranging from 88 to 963jigg-1 using 3-5
mice per dose and 2-6 doses per experiment. Mice were
observed for 7 days after treatment. LDSO/7d values and
confidence limits were derived using pooled data from 2
independent experiments by probit analysis, using the
Generalised Interactive Modelling Programme (GLIM) of
the Royal Statistical Society of London.
Statistics
Significance levels were determined by using Student t-test.
Results
Effects of WBH and Ro 03-8799 on core and tumour
temperature
Figure 1 shows the core (rectal) and central tumour
temperature of unanaesthetised mice, lightly restrained with
string or in perspexjigs, which were subjected to 50min WBH
in an incubator set at an air temperature of 44°C. Mice
restrained in this way exhibited average core temperatures of
35°C prior to heating. Rectal temperatures increased steadily
during the first 15min of WBH, reaching a stable 41°+0.5°C
for the rest of the heating period. Tumour core temperatures
were 4-50C below rectal values at the start of WBH, but
rapidly equilibrated with rectal temperatures after the initial
10min heating. Tumour cooling was also more rapid after
WBH as compared to core temperatures. This heat treatment
produced an average weight loss of 2.0, 3.9 and 6.4% after
10, 30 and 50min WBH respectively.
Since some nitroimidazoles cause a decrease in body
temperature (Gomer & Johnson, 1979; Workman, 1980) we
determined the effects of 175 and 437jgg-g Ro 03-8799 on
rectal temperature in our mice. The results (Figure 2) show
that the high dose produced a rapid drop of 2-3°C, with
recovery to control temperatures after 2h. Both the low dose
and the vehicle control produced a slight transient drop of
0.5 and 1°C respectively, with recovery after 1 h. Small
numbers of mice were also administered HBSS vehicle, or
Ro 03-8799 (175 or 437pgg-1) i.v. and subjected to WBH
as described above. These animals showed similar
temperature profiles to those in Figure 1.
Effects of WBH on acute toxicity
WBH markedly increased the acute toxicity of Ro 03-8799.
Using pooled data from 2 independent experiments the
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Figure 1 Effects of 50min WBH (see Material and Methods) on
rectal and KHT leg tumour temperature in unanaesthetised,
lightly restrained C3H/He mice. Symbols: * incubator air
temperature; 0 rectal temperature; and 0 temperature at
tumour centre. Results are mean (±2s.e.) of 6 mice, from 5
independent determinations. In this and subsequent diagrams the
shaded area indicates the time and duration of WBH after drug
administration, and the sloped portion the initial thermal
equilibration phase.
(217-310)ugg-1 (95% confidence limits; P<0.001). Deaths in
unheated animals occurred immediately after injection and
usually during or shortly after WBH in heated animals.
Subsequent pharmacokinetic experiments were carried out
at 175pgg-1 (-0.6WBH LD50/7d) with and without WBH,
and at the higher, equitoxic dose of 437 igg- ( - 0.6 control
LD5o07d without heat. No deaths occurred at these doses.
b
Figure 2 The effects of various doses of Ro 03-8799 on the
rectal temperature of C3H/He mice. Symbols: V HBSS vehicle
control, 0 175pgg - Ro 03-8799 i.v.; * 437ugg-1 Ro 03-8799
i.v. Aid A ambient temperature. Results are from a typical
experiment showing the mean+2s.e. with 6 mice per point.
Effects of WBH on Ro 03-8799 plasma pharmacokinetics
Figure 3A shows the plasma elimination time course for
Ro 03-8799 after 175/,gg-1 i.v. Plasma clearance was
biphasic. The distribution (a) phase was rapid, the t1/2CX being
-2min, and essentially complete before heating began. The
terminal (fi) phase was much slower, with a t1l2# (with 95%
confidence limits) of 23.5 (21.8-25.4) min, in good agreement
with previous values at this dose (Stratford et al., 1982).
Since in each of two experiments the exposure during the ac-
phase was small (Vd,xt/Vdar.a=8.8 and 7.4% respectively) the
elimination kinetics were treated as monoexponential and
fitted to a one-compartment model (see Dvorchik and Vessel,
1978). Table I and Figure 3a show that WBH increased
plasma drug concentrations and prolonged the t1/2 by 26%
(P<0.01). There was no alteration in the apparent volume of
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Figure 3 Effects of WBH on the pharmacokinetics of Ro 03-8799 in (a) plasma, (b) KHT tumour and (c) brain from C3H/He
mice. Symbols: A 437 pgg- 1 Ro 03-8799 i.v.; 0 175 pgg-1 Ro 03-8799 i.v.; and 0 175pgg- 1 i.v. +WBH. Pooled data from 2-3
independent experiments with 3-7 mice per point. Results are mean +2 s.e.
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distribution (Vde,,) despite the decrease in total body weight.
Plasma AUCO_G for heated mice was increased by 22%, and
the plasma clearance (P,,) correspondingly reduced. Although
the increase in plasma concentrations by WBH was quite
marked, these were still substantially less than those in
unheated animals treated with the equitoxic high-dose of
Ro 03-8799 (Figure 3a). Thus increased plasma drug
exposure alone could not account for the WBH enhanced
acute lethality.
Effects of WBH on Ro 03-8799 tumour and brain
pharmacokinetics
The effects of WBH on tumour and brain concentrations of
Ro 03-8799 and on various tissue pharmacokinetic
parameters are summarised in Figure 3 (panel b and c) and
Table I respectively. In contrast to the plasma results, WBH
had very little effect on tissue drug concentrations. There was
no significant difference in the elimination half-lives of
Ro 03-8799 from tumour tissue in all three treatment groups
(P>0.05). The tumour AUCoG90min for Ro 03-8799 in the
WBH treated mice was very similar to control values, and
only about a third of the AUCo 90min occurring in unheated
mice treated with the equitoxic high dose. WBH did not
significantly alter the brain tissue t112 (P>0.05). By contrast,
the unheated high-dose group had a significantly longer t1/2
(P<0.01). WBH had no effect on the brain AUCoG 90min and
the value was still only 40% of that for normothermic high-
dose brain.
Table II shows the tumour/plasma and brain/plasma ratios
for heated and control mice administered 175pgg-' Ro 03-
8799 i.v. Tumour/plasma ratios exceeded 100% after 10min
in all animals, and were constant between 20-120min. WBH
consistently reduced these ratios but this decrease was
significant only at 40min (P<0.05). However, the average
tumour/plasma ratio over the period 20-120min was
224+34% (2s.e., n=25) for controls compared to 164+20%
(n=31) for WBH treated animals, and this difference was
highly significant (P<0.01). Unheated mice administered
Table I A summary of the effects of WBH on the pharmacokinetics
of Ro 03-8799 in plasma, KHT tumour and brain tissue from
C3H/He mice
Treatment
Unheated
Tissue Parameter Control + WBH high dose
Dose 175 175 437
(pgg-1)
t1/2 23.5 29.1b 28.2a
(min) (21.8-25.4) (27.5-31.0) (25.3-31.8)
Pcl 3.89 3.19 3.77
Plasma (mlg- h-1)
Vdext 2.20 2.23 2.55
(ml g ')
AUCO -, 44.9 54.8 116
(pgml-'h)
t1/2 28.1 31.8 28.6
Tumour (min) (25.9-30.8) (27.8-37.0) (23.3-37.0)
AUCO-90min 61.6 56.7 177
(ggg
I h)
t1/2 31.0 33.9 44.5b
(min) (27.3-35.8) (30.3-38.4) (38.2-53.3)
BraAn AUCO-90min 85.5 89.3 222
(jgg h)
Parameters were derived using pooled data from 2 independent
experiments which were fitted to a one compartment model. Ninety-
five percent confidence limits are shown in parentheses. Each
experiment involved 4-8 time points with 3-7 mice per point.
ap <0.05 and bp <0.01 significantly different from control.
Table II Effects of WBH on tissue/plasma ratios for Ro 03-8799
(175 pgg-1) in C3H/He mice
Tumour/plasma (%) Brain/plasma (%)
Time after
drug administration Control + WBH Control + WBH
(min)
10 123+32 138+20
(n= 10) (n= 10)
20 184+25 175+28 207+46 220+32
Heating (n-6) (n= =6)Oa (n +6) (n 6)
peid 40 203+12 149+20 315+30 249+56 period (n =3) (n- 6) (n =3) (n-6)
60 250+96 139+28 432+62 281+54b
(n=6) (n=6) (n=6) (n=6)
90 209+52 145+72 433+ 136 307+32
(n=5) (n=7) (n=5) (n=7)
120 266+ 108 213+20 471+60 364+54a
(n =5) (n =6) (n =5) (n =6)
Results are mean+2 s.e., using pooled data from 2 independent
experiments.
ap<0.05 and bp<0.01 significantly different from control.
high-dose Ro 03-8799 had a mean tumour/plasma ratio of
226% between 20-90min, very similar to the low dose
unheated group.
Interestingly, Ro 03-8799 concentrated in brain to a much
greater extent than in tumour (Table II). In unheated low-
dose treated animals equilibration occurred after 40min,
giving a mean steady-state brain/plasma ratio of 444%
between 60-120min. WBH also reduced brain/plasma ratios,
e.g. from 433 to 307% at 90min, and this decrease was
significant at 60 and 120min (P<0.01 and P<0.05
respectively). In addition, heated brain/plasma ratios did not
reach equilibration and tended to increase over the whole
time course. Brain/plasma ratios in unheated mice treated
with high-dose Ro 03-8799 were very similar to those
occurring in unheated low-dose treated animals, being for
example 412 and 415% at 60 and 90min respectively.
The above results show that the enhanced acute toxicity of
Ro 03-8799 induced by WBH does not result from an
increase in drug concentration over the whole brain.
Effects of WBH on the concentrations ofthe Ro 03-8799
N-oxide metabolite, Ro 31-0313
Figure 4 shows the effects of WBH on the plasma
concentrations of Ro 31-0313, the N-oxide metabolite of
Ro 03-8799 (Malcom et al., 1983), following Ro 03-8799
administration. WBH greatly increased the plasma
concentration of Ro 31-0313. The metabolite AUC0_. for
the WBH treated mice increased by 57% from 65.6 to
103pgml-'h, a value only 17% less than that for the high
dose unheated mice. This suggested that Ro 31-0313 might
be responsible for the enhanced toxicity of Ro 03-8799 with
WBH. However, acute toxicity experiments showed that,
when administered i.v., Ro 31-0313 was considerably less
toxic than Ro 03-8799 (LDso57d> 1000pgg1-).
KHT tumour Ro 31-0313 metabolite concentrations were
unaltered by WBH and did not exceed 4pgg- in any
treatment group. Tumour/plasma ratios were 38-69% at 60-
90min.
Concentrations of the N-oxide in brain tissue were
consistently just at or below the limit of detection
('- 1.0pgg-1 Ro 31-0313) and no increase was seen with
WBH.
The effects of WBH on the pharmacokinetics of i.v.
administered Ro 31-0313
To assess whether increased metabolism or decreased
clearance were responsible for the elevated plasma N-oxide
concentrations seen after 175pgg-1 Ro 03-8799 and WBH,
we determined the effects of WBH on the plasma pharmaco-SYSTEMIC HYPERTHERMIA AND Ro 03-8799 PHARMACOKINETICS
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Figure 4 Effects of WBH on the concentrations of the N-oxide
metabolite, Ro 31-0313, in C3H/He mice after Ro 03-8799
administration. Symbols: plasma Ro 31-0313 concentrations
after, 0 175pgg-I Ro 03-8799 i.v.; * 175,ygg-I Ro 03-8799
plus WBH; and C] 436pgg-I Ro 03-8799 i.v. Pooled data from
2 independent experiments with 3-7 mice per point. Results are
mean+2s.e.
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Figure 5 Plasma concentrations of the N-oxide metabolite
Ro 31-0313 in C3H/He mice after 40pgg-1 Ro 31-0313 i.v.
Symbols: * with WBH; and 0 without. Data from 3
independent experiments with 3-8 mice per point. Results are
mean +2 s.e.
kinetics of i.v. administered Ro 31-0313 (40 pgg- 1). This
dose gave N-oxide concentrations similar to those occurring
as a metabolite after 175pgg-1 Ro 03-8799. The results are
summarised in Figure 5 and table III.
After i.v. administration Ro 31-0313 clearance was
biphasic, and the data required analysis by the two-
Table III Effects of WBH on the pharmacokinetics of
i.v. administered Ro 31-0313 in C3H/He mice
Parameters Control + WBH
Dose (/tgg-') 40 40
A (ugml-1) 101 101
(62.2-162) (53.4- 173)
B (pgml-1) 15.2 22.2
(11.3-20.4) (13.9-35.5)
t112a (min) 3.62 2.99
(3.04-4.49) (2.50-3.73)
t1/2fl (min) 23.1 21.6
(20.5-26.6) (17.9-27.1)
AUCO_o (pgml-'h) 17.2 18.5
Pcl (mlg ' h 1) 2.32 2.17
Vdarea (mlg 1) 1.29 1.13
Parameters were derived using pooled data from 3
independent experiments which were fitted to the 2
compartment open model:
Ct=Ae-`+Be- '. Each experiment involved 5-7
time points with 3-8 mice per point.
compartment open model. In normothermic mice the oc-phase
t1/2 was 3.62 (3.03-4.44) min while the f-phase t1/2 was 23.1
(20.5-26.6) min. Plasma Ro 31-0313 concentrations were
consistently higher in WBH treated animals compared to
controls and this difference was clearly significant at 20min
(P<0.01) but not at later times (P>0.05). Although the
change in total AUC was modest, the contribution from the
f-phase was in fact increased by 36%, In addition, the
apparent volume of distribution (Vdarea) was reduced by 13%.
Effects of WBH on the N-oxidation ofRo 03-8799 in mice
Table IV compares the effects of WBH on the plasma
concentrations of Ro 31-0313, either produced as a
metabolite of Ro 03-8799 or administered i.v. After the first
40min there is a significantly (P<0.01) greater elevation in
N-oxide concentration in mice treated with Ro 03-8799 and
WBH compared to those treated with Ro 31-0313 and WBH.
This shows that in addition to its effects on Ro 31-0313
clearance described above, WBH also enhances its metabolic
production from Ro 03-8799.
The effects of WBH on 51Cr EDTA clearance
Since Ro 03-8799 is eliminated by both metabolic and renal
clearance (Walton et al., 1985) we investigated the effects of
WBH on GFR using 51Cr EDTA (Chantler et al., 1969).
Figure 6 shows that WBH almost completely inhibits 5tCr
EDTA clearance specifically during the heating period,
resulting in a two-fold decrease in total plasma clearance
from 1.14 to 0.58mlg-'h-'.
Table IV Effect of WBH on plasma Ro 31-0313
concentrations in WBH treated C3H/He mice given either
Ro 03-8799 (175pgg- ) or Ro31-0313 (40pgg-1) i.v.
Time after Percentage increase in plasma Ro 31-0313
injection concentrations in WBH treated mice
(min) compared to unheated controls
After Mean After Mean
Ro 03-8799 (±2s.e.) Ro 31-0313 (±2s.e.)
20 17 34
40 63 ) 29
60 81 74.5 60 36.8a
90 80 ' (8.3) 24 r (16.0)
120 74J 34 J
Thesevalues werederived usingthedatashown inFigures4and5.
aSignificantly different from each other (P<0.01).
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Discussion
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distribution volume. WBH also altered th
of i.v. administered Ro 31-0313, the N-c
Ro 03-8799. Total plasma N-oxide cc
increased with hyperthermia, particularly
This was accompanied by a 6% decrease i
but no marked alteration in t1/2c. or tl/
was only slightly increased despite a 360,
phase component. The 6% loss of body
with this heating technique may also h
these pharmacokinetic changes.
In view of the number of processes involved in drug
disposition in vivo, it is perhaps not surprising that the
pharmacokinetic effects of WBH varies between drugs.
Further comparative studies are required to see if some
general principles can be established.
Ro 03-8799 is a basic drug designed to concentrate in acid
urine in the hope of accelerating urinary excretion and
thereby reducing body exposure (Wardman, 1979). Ro 03-8799
is eliminated rapidly not only by urinary excretion but also
by metabolic N-oxidation in both mice (Walton et al., 1985)
and man (Roberts et al., 1986; Allen et al., 1984). The precise
mechanism of urinary elimination of Ro 03-8799, in
particular the relative importance of active secretion and
reabsorption versus simple glomerular filtration, is unknown.
We show here that glomerular filtration is inhibited almost
completely during the heating period, returning to normal
immediately afterwards. This will contribute to reduced
Ro 03-8799 clearance but cannot be the complete
explanation as drug elimination was decreased uniformly
over the whole time course and by only 18% compared to
the 49% reduction in GFR. Similar reductions (51%)
occurred in humans subjected to combined dehydration,
\. T exercise and mild heat stress (Smith et al., 1952), an effect
mainly attributed to decreased renal blood flow (Radigan &
Robinson, 1950). Reduction in plasma pH would also
decrease renal clearance by reducing the pH gradient
between plasma and urine, and hence the rate of Ro 03-8799
accumulation into acid urine. Such a change may occur in
120 160 mice during WBH due to metabolic acidosis, and blood pH
is markedly decreased in dogs after WBH (Macy et al.,
la clearance of 51Cr 1985).
heated mice. Results A novel feature of this basic radiosensitizer is its ability to
4nt. Data from 2 concentrate in tissue giving tumour/plasma and brain/plasma
ratios of 200%-400% after equilibration (Allen et al., 1984;
Roberts et al., 1986). In unheated mice, high-dose
Ro 03-8799 (437 ugg-') produced higher plasma and tissue
concentrations compared to low doses (175pgg-1) although
tissue/plasma ratios were very similar. By contrast WBH
markedly enhances increased low-dose Ro 03-8799 plasma concentrations
tizer Ro 03-8799 in without affecting those in tumour and brain, resulting in
complex effect on reduced tissue/plasma ratios. This failure of heated tissue to
cantly reduces the equilibrate with the increased plasma drug concentrations
th no alteration in after WBH may involve a complex interaction of several
ilting in reduced factors such as drug delivery and uptake, tissue pH and/or
plasma levels of the drug metabolism.
y stimulating its A reduction in blood perfusion would impair tissue uptake
hrough a reduction leading to a decreased tissue/plasma ratio. However, tissue
blood flow tends to increase at temperatures up to 42°C,
mbined with hyper- with vascular stasis occurring predominantly at higher
f its effects on drug temperatures and longer times than those used here (see
naugh et al. (1978) Reinhold et al., 1985).
Lot alter adriamycin WBH may also decrease tissue pH through stimulation of
/2a. In dogs WBH anaerobic glycolysis (see Reinhold et al., 1985). Our measure-
)lasma adriamycin ments do not distinguish intracellular from extracellular
trast, Honess et al. drug and we have no data on intracellular/extracellular pH
phalan was reduced changes after WBH. In view of these unknown variables it is
in mice; this was difficult to predict the effects of possible pH changes on
Lpparent volume of overall tissue concentrations. Simplistically, however, a
i/2- Using almost reduction in tissue pH would be likely to increase the total
;tudy, we show here amount of the basic drug by ion-trapping, leading to a higher
:ed by 18% and tissue/plasma ratio.
ig in higher plasma Little is known about the effects of hyperthermia on drug
'er no change in metabolism. The reduced Ro 03-8799 tissue/plasma ratios
ie pharmacokinetics after WBH may reflect heat-stimulated reductive metabolism
)xide metabolite of to non-UV absorbing metabolites, (Schwartz & Hofheinz,
)ncentrations were 1982). The possibility that such differences resulted from ex
during the ,B-phase. vivo metabolism were minimised by rigorous sample handling
in plasma clearance, techniques. Honess et al. (1980) reported 50-70% lower
2p. The total AUC tumour MISO concentrations in locally heated mouse leg
' increase in the fi- tumours; but this may have occurred through reduced drug
y weight associated uptake as well as enhanced reductive metabolism. Other
ave contributed to workers demonstrated increased levels of reduced adriamycin
metabolities, particularly aglycones, in locally heated mouse
or Ogg
iti ti
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tumours (Magin et al., 1980) as well as other normal rabbit
tissues following WBH (Mimnaugh et al., 1978). In more
direct support of our hypothesis we have recently shown that
mild hyperthermia (41°C) can enhance benznidazole nitro-
reduction in vitro (Walton et al., unpublished results).
We also present evidence of hyperthermia-potentiated
oxidative metabolism of Ro 03-8799 to its N-oxide, Ro 31-
0313. N-oxidation is regarded as predominantly involving
components of the hepatic mixed-function oxidases (MFO)
(Bickel, 1969). We have also shown that hyperthermia (41°C)
enhances oxidative 0-demethylation of MISO by MFO in
vitro (Walton, Bleehen & Workman, unpublished results). In
contrast Collins and Skibba (1983), showed using an isolated
rat liver perfusion technique, that the t 22S of antipyrine and
cyclophosphamide were increased at 42 compared to 37°C,
concluding that hyperthermia depressed hepatic MFO
activity. This may reflect the different model systems and
heat doses employed, as well as the particular drugs and
metabolic reactions involved.
The 3-fold increase in Ro 03-8799 acute lethality with
WBH is similar to the doubling of MISO acute toxicity by
local hyperthermia, where core temperatures approached
41°C (Overgaard, 1979; 1980). The nature of Ro 03-8799
acute toxicity, resulting in death immediately after
administration in normothermic mice and during or shortly
after WBH in heated mice, is at present unknown. At lethal
doses of Ro 03-8799 normothermic mice suffered rapid
convulsions characteristic of central nervous system toxicity.
This may be related to the acute CNS affect seen with
Ro 03-8799 in man (Roberts et al., 1986; Saunders et al.,
1984). Considerable evidence suggests that exposure of the
nervous system to nitroimidazoles is correlated to their
neurotoxicity (e.g. Brown & Workman, 1980; Conroy et al.,
1982). However, we found brain Ro 03-8799 concentrations
were minimally altered by WBH, being substantially less
than in unheated animals treated with equitoxic high doses.
It seems that the increased lethality cannot be attributed to
elevated brain exposure to the parent drug. However,
reductive metabolism of nitroimidazoles generates highly
reactive and toxic metabolities (Rauth, 1984). Consequently
increased toxicity may result from hyperthermia-enhanced
Ro 03-8799 reductive metabolism.
Other organ toxicities also occur, e.g., chronic Ro 03-8799
administration caused severe hepatotoxicity in monkeys
(Roche Products, 1982). WBH tends to produce liver
temperatures 1-2°C above core temperatures, also resulting
in hepatotoxicity after prolonged exposures (Fletcher et al.,
1982). Thus liver damage may be important with the
combination. If different organ toxicities do operate with
Ro 03-8799 in unheated and heated animals, correlation with
the measured pharmacokinetic parameters would not be
expected.
High nitroimidazole doses produce large decreases in
mouse core temperature (e.g. Workman, 1980) and this has a
protective effect on the acute lethality of MISO (Gomer &
Johnson, 1979) possibly through decreased metabolic
activity. Thus the enhanced toxicity of high doses of Ro 03-
8799 with WBH may arise from abolition of the protective
hypothermia together with an attendant increase in Ro 03-
8799 reductive activation.
In conclusion, WBH substantially increased the acute
toxicity of Ro 03-8799. It also increased plasma Ro 03-8799
concentrations, partly as a result of inhibited glomerular
filtration. Absolute tumour and brain drug concentrations
were unaltered, giving reduced tissue/plasma ratios. These
WBH-induced alterations in Ro 03-8799 pharmacokinetics
probably contribute to its enhanced toxicity but cannot
completely explain it. There was no clear correlation between
brain drug levels and increased toxicity. However, WBH did
enhance the hepatic N-oxidation of Ro 03-8799 in vivo, and
hyperthermia potentiated metabolism, particularly nitro-
reduction, may be involved in the increased toxicity of this
combination. In view of this possibility and the cytotoxic
potential of bioreductive metabolism, we are investigating the
value of Ro 03-8799 or other bioreductively activated drugs
in combination with localised tumour hyperthermia.
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